Introduction
============

Cancer has been one of the major causes of death and threats to global health due to its high morbidity and mortality ([@B51]). Meanwhile, the global incidence of cancer is rapidly increasing ([@B44]). Study shows that in 2017 there are 1,688,780 new cancer cases and 600,920 cancer deaths in the United States ([@B41]). Many researchers have been focusing on identifying new tumor biomarkers which can be associated with cancer screening, diagnosis, prognosis, and evaluation of treatment efficacy ([@B36]; [@B8]; [@B15]). Currently, even though various therapeutic methods have made significant achievements in cancer therapy, the 5-year-survival rate still remains unsatisfactory in cancer patients ([@B7]). Therefore, it is necessary to identify new prognostic biomarkers for accurate prognosis prediction.

High mobility group protein A2 (HMGA2) is a small non-histone chromosomal protein. It has no intrinsic transcriptional activity, but can modulate transcription by altering chromatin architecture ([@B11]; [@B33]). Normally, HMGA2 protein is highly expressed in embryogenesis, while its expression is almost undetectable in most adult and differentiated tissues ([@B4]; [@B38]; [@B10]). An increasing number of recent studies have suggested that HMGA2 could highly express in many human malignant cells, and it can participate in different cellular activities including cell cycle regulation, differentiation and senescence ([@B49]; [@B12]). HMGA2 overexpression has been reported to be associated with tumorigenesis and progression in many human cancers such as esophageal squamous cell cancer ([@B59]), lung cancer ([@B17]), pancreatic cancer ([@B35]), breast cancer ([@B50]) and colorectal cancer ([@B47]). Meanwhile, plenty of studies showed that elevated HMGA2 expression in cancer tissues was associated with poor survival in patients such as lung cancer ([@B39]), oral squamous cell carcinoma ([@B28]), ovarian cancer ([@B40]) and metastatic breast cancer ([@B18]). However, due to the limitations of sample size and research programs, single studies are inadequate to obtain a reliable assessment of the potential prognostic value of HMGA2. Therefore, we conducted a meta-analysis of a large sample size to gain better insight into this problem. In addition, The Cancer Genome Atlas (TCGA) databases were utilized to validate the result of our meta-analysis.

Materials and Methods {#s1}
=====================

Study Strategy
--------------

Method of the analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([@B29]). We searched PubMed, Embase, Web of Scienceand Cochrane Library databases for relevant articles from January 1, 2000 to August 17, 2017. The research subject and article language were limited to human and English. Both MeSH terms and free-text words were used as strategy to increase the sensitivity of the searching. The search terms included: ("cancer" OR "tumor" OR "neoplasm" OR "carcinoma") AND ("High mobility group protein A2" OR "HMGA2") AND ("prognosis" OR "prognostic" OR "outcome"). We also manually screened the references of retrieved articles to identify more eligible studies that may have been missed by the key word search.

Inclusion and Exclusion Criteria
--------------------------------

Two authors (Ben Huang and Jiayi Yang) independently selected all eligible articles according to the criteria: (1) studies that showed the association between HMGA2 expression and prognosis of cancers patients as well as reporting survival data; (2) studies that provided related clinicopathological parameters; (3) studies in which number of patients were more than 40.

Exclusion criteria were as followed: (1) articles that lack data; (2) reviews, letters, case reports or duplicates.

Data Extraction and Quality Assessment
--------------------------------------

Two investigators independently extracted the relevant data from the included articles using a predefined standardized form. We extracted the following data from each study: (1) publication year; (2) countries; (3) first author's name; (4) types of cancers; (5) detection methods; (6) number of patients; (7) cut off values; (8) clinicopathological parameters; (9) relevant data for OS/PFS/DFS. If the articles did not offer HRs and its 95% CIs directly, we then used the Engauge Digitizer 4.1 software ([@B43]) to extract the data from the survival curves. Disagreements in the literature assessment were resolved through consensus with a third reviewer (June Wang). Furthermore, we used the Newcastle-Ottawa Scale (NOS) to assess the quality of these included studies ([@B57]). According to the NOS criteria, studies with a score of ≥7 were considered to be high quality articles.

Extraction and Analysis of TCGA Datasets
----------------------------------------

Datas for HMGA2 expression and clinical information in TCGA were extracted from the UALCAN^[1](#fn01){ref-type="fn"}^ ([@B2]). In all, 33 types of cancers were analyzed. There were 9944 subjects that have both HMGA2 expression data and survival data. Accorrding to the transcripts per million (TPM) expression value, the HMGA2 expression levels were divided into high expression group (with TPM values above upper quartile) and low/median expression group (with TPM values below upper quartile). Then, according to the survival data of patients in TCGA datasets, Kaplan*--*Meier survival analyses were performed and overall survival plots were generated. The difference between high gene expression and low/medium gene expression was compared by Log-rank test.

Outcomes Analysis
-----------------

Pooled HRs and corresponding 95% CIs were calculated to evaluate the impact of HMGA2 expression on overall survival and disease-free survival. ORs with corresponding 95% CIs were calculated to assess the correlation between HMGA2 expression and clinicopathological features. Chi square-based *Q* test and *I*^2^ test were used to evaluate the heterogeneity across the studies. A fixed-effect model was adopted if the heterogeneity was not significant (*I*^2^ \< 50% or *P*-value \> 0.05). Otherwise, a random-effect model was selected. Besides, subgroup analysis was performed to explore the sources of heterogeneity. Meanwhile, we used Stata12.0 software (Stata Corporation, College Station, TX, United States) to analyze the sensitivity and publication bias in this study. All the statistical tests were two-sided, and *P* \< 0.05 was considered statistically significant.

Results
=======

The Description of the Included Studies
---------------------------------------

As shown in the **Figure [1](#F1){ref-type="fig"}**, 846 records were obtained by searching the databases. After screening the titles and abstracts, 807 articles were excluded. Then 16 papers were excluded because of no available data or non English papers. Eventually, 23 articles were enrolled ([@B30]; [@B47]; [@B56]; [@B52]; [@B37]; [@B55]; [@B1]; [@B16]; [@B19], [@B20]; [@B13]; [@B14]; [@B23]; [@B54]; [@B31]; [@B48]; [@B50]; [@B59]; [@B61]; [@B6]; [@B9]; [@B27]; [@B42]). In total, 15 types of cancers were included in this meta-analysis including ampullary adenocarcinoma, breast cancer, colorectal cancer, clear cell renal cell carcinoma (ccRCC), esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinomas, nasopharyngeal carcinoma, ovarian carcinoma, oral squamous cell carcinoma, pancreatic ductal adenocarcinoma, and tongue squamous cell carcinoma. In these studies, the level of HMGA2 expression was all detected in collected tumor tissues. Almost all the studies performed immunohistochemistry (IHC) to evaluate the expression of HMGA2 while only one of them used the relative quantitative reverse transcription-polymerase chain reaction (qT-PCR). The main features of the eligible studies were listed in **Table [1](#T1){ref-type="table"}**.

![Flow diagram of study selection.](fphys-09-00776-g001){#F1}

###### 

Characteristics of eligible studies in this meta-analysis.

  First author   Year   Country   No. of patients   Tumor type                              Method   Cut-off            Outcome   Analysis              Nos
  -------------- ------ --------- ----------------- --------------------------------------- -------- ------------------ --------- --------------------- -----
  Strell         2017   Sweden    253               Pancreatic ductal denocarcinoma         ICH      IHC score ≥ 1      OS        Multivariate          7
  Strell         2017   Sweden    155               Ampullary adenocarcinoma                ICH      IHC score ≥ 1      OS        Multivariate          7
  Mito           2017   USA       91                Esophageal Adenocarcinoma               ICH      NR                 OS        Multivariate          8
  Fang           2017   China     148               Oral Squamous Cell Carcinoma            ICH      IHC ≥ 30%          OS/DFS    Multivariate          9
  Wei            2017   China     96                Esophageal squamous cell carcinoma      ICH      IHC score ≥ 4      OS        Multivariate          8
  Gunther        2016   Germany   202               Head and neck squamous cell carcinoma   RT-PCR   upper quartile     OS/PFS    Multivariate          8
  Wu             2016   China     273               Breast cancer                           ICH      NR                 OS        Multivariate          7
  Zhao           2016   China     60                Tongue squamous cell carcinoma          ICH      NR                 OS/DFS    Multivariate          9
  Na             2016   China     162               Clear cell renal cell carcinoma         ICH      IHC score \> 106   OS        Multivariate          9
  Zhang          2016   China     127               Esophageal squamous cell carcinoma      ICH      IHC score ≥ 4      OS        Multivariate          8
  Jun            2015   Korea     110               Gastric cancer                          ICH      IHC score ≥ 5      RFS       Multivariate          9
  Kim            2015   Korea     74                Ovarian carcinoma                       ICH      NR                 OS        Multivariate          9
  Liu            2015   China     116               Nasopharyngeal carcinoma                ICH      IHC score ≥ 4      OS        Multivariate          8
  Xia            2015   China     124               Nasopharyngeal carcinoma                ICH      IHC score ≥ 6      OS        Multivariate          8
  Lee            2015   Korea     170               Gastric cancer                          ICH      IHC score ≥ 9      OS        Multivariate          9
  Kong           2014   China     158               Gastric cancer                          ICH      IHC score ≥ 1      OS        Multivariate          8
  Lee            2014   China     55                Intrahepatic cholangiocarcinomas        ICH      IHC \> 5%          OS        Multivariate          7
  Rizzi          2013   Italy     103               Colorectal cancer                       ICH      IHC ≥ 5%           OS        Kaplan-Meier curves   7
  Califano       2013   Italy     113               Ovarian cancer                          ICH      IHC ≥ 10%          OS/DFS    Multivariate          7
  Yamazaki       2013   Japan     91                Head and neck squamous cell carcinoma   ICH      IHC score ≥ 1      OS        Kaplan-Meier curves   8
  Wu             2012   China     107               Hepatocellular Carcinoma                ICH      IHC ≥ 10%          OS        Multivariate          8
  Yang           2011   China     148               Bladder cancer                          ICH      IHC ≥ 50%          PFS/RFS   Multivariate          9
  Wang           2011   China     89                Colorectal Cancer                       ICH      IHC ≥ 5%           OS        Multivariate          8
  Wang           2011   China     191               Colorectal Cancer                       ICH      IHC ≥ 5%           OS        Multivariate          8
  Motoyama       2008   Japan     110               Gastric cancer                          ICH      NR                 OS        Multivariate          8

ICH, Immunohistochemistry; NR, Not Reported; NOS, Newcastle-Ottawa Scale; OS, overall survival; DFS, disease-free survival

.

Meta-Analysis of HMGA2 Expression on OS/DFS
-------------------------------------------

Among the included papers, 23 studies involving 3068 patients showed the data of both HMGA2 expression and OS of the patients. As displayed in **Figure [2](#F2){ref-type="fig"}**, there was no obvious heterogeneity across these studies (*I*^2^ = 0.2%, *P* = 0.458). Thus, we used the fixed-effect model to evaluate the pooled HRs and 95% CIs. As a result, the pooled data indicated that elevated HMGA2 was significantly associated with poor OS in patients with cancers (HR = 1.88, 95% CI = 1.68-2.11, *P* \< 0.001). Meanwhile, there were five studies showed the association between HMGA2 expression level and DFS in the included studies. Heterogeneity test indicated there was an obvious heterogeneity (*I*^2^ = 64.6%), then the random-effect model was used. Pooled results also demonstrated that high HMGA2 expression was associated with shorter DFS in cancer patients (HR = 2.49, 95% CI = 1.44-4.28) (**Figure [3](#F3){ref-type="fig"}**).

![Forest plot of studies evaluating hazard ratios of high expressed HMGA2 and the overall survival of cancer patients.](fphys-09-00776-g002){#F2}
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Subgroup Analysis for OS
------------------------

We then made a subgroup analysis for OS, in which the patients were stratified based on cancer type, analysis type and sample size (**Table [2](#T2){ref-type="table"}**). There was only one study for each that evaluated the association between HMGA2 expression and OS in pancreatic ductal adenocarcinoma, ampullary adenocarcinoma, breast cancer, ccRCC, intrahepatic cholangiocarcinoma, and hepatocellular carcinoma. Therefore, we defined these cancers as "other cancers" in this subgroup. Results show that high expression level of HMGA2 was associated with poor OS in gastric cancer (HR = 1.94, 95% CI = 1.42-2.65, *P* \< 0.001), head and neck cancer (HR = 1.77, 95% CI = 1.37-2.29, *P* \< 0.001), colorectal cancer (HR = 2.13, 95% CI = 1.48-3.05, *P* \< 0.001) and other cancers (HR = 2, 95% CI = 1.68-2.40, *P* \< 0.001), but not esophageal cancer (HR = 1.15, 95% CI = 0.55-2.37, *P* = 0.712) and ovarian cancer (HR = 1.07, 95% CI = 0.55-2.37, *P* = 0.712). As a result, we found that high level of HMGA2 was related with poor OS in 13 types of cancers. Meanwhile, in the subgroups based on sample size and analysis type, we also found the association between HMGA2 and poor OS except for multivariate analysis.

###### 

Subgroup analyses of pooled HR for OS.

  Categories                 No. of studies   No. of patients   Pooled HR (95% CI)   Heterogeneity          
  -------------------------- ---------------- ----------------- -------------------- --------------- ------ -------
  **\[1\] OS**               23               3068              1.88 (1.68-2.11)     0               0.2    0.458
  **\[2\] Cancer type**                                                                                     
  1\) Colorectal cancer      3                383               2.13(1.48-3.05)      0               0      0.834
  2\) Esophageal cancer      3                314               1.15 (0.55-2.37)     0.712           80     0.007
  3\) Gastric cancer         3                438               1.94 (1.42-2.65)     0               11.4   0.324
  5\) Head and neck cancer   6                741               1.77 (1.37-2.29)     0               42.8   0.12
  6\) Ovarian cancer         2                187               1.07 (0.55-2.08)     0.835           31.6   0.227
  7\) Others                 8                1213              2.09 (1.76-2.47)     0               0      0.43
  **\[3\] Analysis**                                                                                        
  Multivatiate               21               2874              1.80 (1.60-2.02)     0               48.9   0.006
  Survival curves            2                194               1.71 (0.93-3.15)     0.085           0      0.864
  **\[4\] Sample size**                                                                                     
  ≥115                       12               2079              1.85 (1.61-2.13)     0               22     0.227
  \<115                      11               989               1.68 (1.21-2.33)     0.002           59.1   0.006

OS, overall survival; HR, hazard ratio

.

HMGA2 Overexpression and Clinical Pathological Features
-------------------------------------------------------

In order to gain further insight into the value of HMGA2, we investigated the association between HMGA2 level and certain clinicopathological parameters in cancers (**Table [3](#T3){ref-type="table"}**). The expression level of HMGA2 was significantly associated with TNM stage (OR = 1.65, 95% CI = 1.12-2.44, *P* = 0.011, random-effect model), tumor differentiation (OR = 1.94, 95% CI = 1.51-2.51, *P* \< 0.001, fix-effect model), tumor invasion depth (OR = 1.71, 95% CI = 1.35-3.16, *P* \< 0.001, fix-effect model), lymph node metastasis (OR = 1.86, 95% CI = 1.27-2.72, *P* = 0.001, random-effect model), lymphovascular invasion (OR = 2.18, 95% CI = 1.49-3.18, *P* \< 0.001, fix-effect model), vascular invasion (OR = 2.1, 95% CI = 1.42-3.10, *P* \< 0.001, fix-effect model) and distant metastasis (OR = 3.45, 95% CI = 2.06-5.75, *P* \< 0.001, fix-effect model). No significant correlations were found with age (OR = 0.99, 95% CI = 0.74-1.32, *P* = 0.931, fixed-effect model), gender (OR = 1, 95% CI = 0.84-1.18, *P* = 0.974, fixed-effect model) and tumor size (OR = 0.77, 95% CI = 0.53-1.14, *P* = 0.19, fixed-effect model). The results indicated that high HMGA2 expression in human cancers was linked to aggressive biological behavior.

###### 

Clinicopathological features of the enrolled studies with high expressed HMGA2 in patients with cancer.

  Clinicopathological parameters                   Studies   No. of patients   Risk of high HMGA2 OR (95% CI)   Significant *Z*   *p*-value   Heterogeneity *I*^2^ (%)   *p*-value   Model
  ------------------------------------------------ --------- ----------------- -------------------------------- ----------------- ----------- -------------------------- ----------- ----------------
  Age (\<50 vs ≥50)                                6         919               0.99 (0.74-1.32)                 0.09              0.931       0                          0.836       Fixed effects
  Gender (male vs female)                          21        2803              1.00 (0.84-1.18)                 0.03              0.974       27.3                       0.122       Fixed effects
  Tumor size (\<3 cm vs ≥3 cm)                     4         543               0.77 (0.53-1.14)                 1.31              0.19        0                          0.756       Fixed effects
  TNM stage (III-IV vs I-II)                       16        2292              1.65 (1.12-2.44)                 2.53              0.011       68.4                       0           Random effects
  Tumor differentiation (moderate/well vs poor)    10        1317              1.94 (1.51-2.51)                 5.11              0           46.9                       0.049       Fixed effects
  Tumor invasion depth (T3--T4 vs T1--T2)          13        1767              1.71 (1.35-3.16)                 4.52              0           40.7                       0.063       Fixed effects
  Distant metastasis (Positive vs negative)        6         721               3.45 (2.06-5.75)                 4.73              0           41.7                       0.127       Fixed effects
  Lymph node metastasis (Positive vs negative)     17        2289              1.86 (1.27-2.72)                 3.19              0.001       74.9                       0           Random effects
  Lymphovascular invasion (Positive vs negative)   5         629               2.18 (1.49-3.18)                 4.02              0           31.4                       0.212       Fixed effects
  Vascular invasion (Positive vs negative)         5         655               2.1 (1.42-3.10)                  3.73              0           0                          0.464       Fixed Effects

Sensitivity Analyses and Publication Bias
-----------------------------------------

In order to assess whether a single study could significantly affect the overall result, we performed sensitivity analyses. Results demonstrated the individual study had no influence on our meta-analysis (**Figure [4](#F4){ref-type="fig"}**), which supported credibility of our analysis. In addition, Funnel plots and Begg's test were used to evaluate the publication bias of this meta-analysis. Results showed that there was no publication bias existed in studies on HMGA2 overexpression in association with OS (*P* = 0.597. **Figure [5A](#F5){ref-type="fig"}**) and DFS (*P* = 0.462. **Figure [5B](#F5){ref-type="fig"}**).
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The Expression of HMGA2 in Cancers Based on TCGA Datasets
---------------------------------------------------------

We then analyzed the expression of HMGA2 in different cancers in TCGA datasets through UALCAN, which was an interactive web-portal to perform in-depth analyses of TCGA gene expression data ([@B2]). HMGA2 was detected in 21 types of cancers and corresponding normal tissues. According to *P* value obtained from log-rank test, we found that the HMGA2 expression was significantly higher than corresponding normal tissues in 17 types of cancers except glioblastoma multiforme, kidney chromophobe, kidney renal clear cell carcinoma and prostate adenocarcinoma (**Table [4](#T4){ref-type="table"}**).

###### 

The difference of HMGA2 expression in cancers and corresponding normal tissues in TCGA datasets.

  Types of cancer                         TCGA dataset   No. of cancer tissues   No. of normal tissues   *P* value
  --------------------------------------- -------------- ----------------------- ----------------------- -----------
  Bladder urothelial carcinoma            TCGA-BLCA      408                     19                      \<0.0001
  Breast invasive carcinoma               TCGA-BRCA      1097                    114                     \<0.0001
  Cervical squamous cell carcinoma        TCGA-CESC      305                     3                       \<0.0001
  Cholangiocarcinoma                      TCGA-CHOL      36                      9                       0.032
  Colon adenocarcinoma                    TCGA-COAD      286                     41                      \<0.0001
  Esophageal carcinoma                    TCGA-ESCA      184                     11                      \<0.0001
  Glioblastoma multiforme                 TCGA-GBM       156                     5                       0.052
  Head and Neck squamous cell carcinoma   TCGA-HNSC      520                     44                      \<0.0001
  Kidney chromophobe                      TCGA-KICH      67                      25                      0.316
  Kidney renal clear cell carcinoma       TCGA-KIRC      533                     72                      0.071
  Kidney renal papillary cell carcinoma   TCGA-KIRP      290                     32                      \<0.0001
  Liver hepatocellular carcinoma          TCGA-LIHC      371                     50                      \<0.0001
  Lung adenocarcinoma                     TCGA-LUAD      515                     59                      \<0.0001
  Lung squamous cell carcinoma            TCGA-LUSC      503                     52                      \<0.0001
  Ovarian serous cystadenocarcinoma       TCGA-OV        178                     4                       \<0.0001
  Pheochromocytoma and Paraganglioma      TCGA-PCPG      179                     3                       0.011
  Prostate adenocarcinoma                 TCGA-PRAD      497                     52                      0.201
  Rectum adenocarcinoma                   TCGA-READ      166                     10                      \<0.0001
  Stomach adenocarcinoma                  TCGA-STAD      415                     34                      \<0.0001
  Thyroid carcinoma                       TCGA-THCA      505                     59                      \<0.0001
  Uterine corpus endometrial carcinoma    TCGA-UCEC      546                     35                      \<0.0001

Validation by TCGA Datasets
---------------------------

In order to validate the result of our meta-analysis, TCGA datasets were analyzed to explore whether HMGA2 could be involved in human cancers and affect patients' survival. In total, 9944 patients with 33 types of cancer were obtained (**Table [5](#T5){ref-type="table"}**). Significant association between high expressed HMGA2 and poor overall survival in patients was found in 14 types of cancers. They were adrenocortical carcinoma, bladder urothelial carcinoma, brain lower grade glioma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, acute myeloid leukemia, liver hepatocellular carcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, sarcoma, uterine corpus endometrial carcinoma and uveal melanoma (**Figure [6](#F6){ref-type="fig"}**).

###### 

The difference of overall survival in cancer patients with high HMGA2 expression vs low/median expression.

  Cancer type   No. of cancer tissues   *P* value         
  ------------- ----------------------- ----------- ----- ----------
  ACC           79                      20          59    \<0.0001
  BLCA          406                     102         304   0.023
  BLGG          511                     128         383   \<0.0001
  BRCA          1081                    273         808   0.72
  CESC          291                     77          214   0.3
  CHOL          36                      9           27    0.14
  COAD          279                     67          212   0.38
  ESCA          184                     46          138   0.76
  GBM           152                     39          113   0.13
  HNSCC         519                     130         389   0.00016
  KICH          65                      17          48    0.39
  KIRC          531                     134         397   \<0.0001
  KIRP          287                     72          215   0.043
  LAML          163                     41          122   0.049
  LIHC          365                     89          276   0.0092
  LUAD          502                     123         379   0.015
  LUSC          494                     123         371   0.28
  DLBC          47                      11          36    0.21
  MESO          85                      22          63    0.56
  OVSC          303                     76          227   0.83
  PAAD          177                     45          132   0.019
  PCPG          179                     45          134   0.23
  PRAD          497                     125         372   0.0068
  READ          165                     41          124   0.52
  SARC          259                     65          194   0.019
  SKCM          459                     115         344   0.61
  STAD          392                     98          294   0.49
  TGCT          134                     30          104   0.26
  THYM          119                     30          89    0.052
  THCA          504                     127         377   0.64
  UCS           56                      15          41    0.57
  UCEC          543                     136         407   0.023
  UVM           80                      20          60    0.035

ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BLGG, brain lower grade glioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSCC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; LAML, acute myeloid leukemia; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; MESO, mesothelioma; OVSC, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma

.
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Considering the TCGA datasets and our meta-analysis, we identified correlation between high HMGA2 expression and head and neck cancer, pancreatic ductal adenocarcinoma, ccRCC, hepatocellular carcinoma, esophageal adenocarcinoma and ovarian carcinoma, except breast cancer and gastric cancer.

Discussion
==========

Recently, increasing evidences have suggested that HMGA2 protein could participate in aggressive tumor growth ([@B34]; [@B12]), stem cell self-renewal ([@B32]; [@B45]), DNA damage response ([@B21]), and tumor cell differentiation ([@B40]). However, the precise role of HMGA2 in malignant transformation and the gene regulation of tumorigenesis were still unclear ([@B46]). Data have collectively indicated that the high level of HMGA2 could serve as a novel biomarker to evaluate the prognosis of patients with various cancers such as breast cancer ([@B50]), lung cancer ([@B5]), ovarian cancer ([@B25]), colorectal cancer ([@B47]), and gastric cancer ([@B20]). However, single studies may not be sufficient and accurate and whether HMGA2 could be used as a prognostic biomarker in human cancers was still unclear.

To the best of our knowledge, our meta-analysis was the first study to evaluate the significance of HMGA2 and prognostic value in various cancers through drawing data from both the TCGA datasets and published studies. In this paper, 15 types of cancers involving 3068 patients were included. Then, based on TCGA datasets, we analyzed 9944 patients with 33 types of cancers. The meta-analysis results suggested that high expression of HMGA2 was associated with shorter OS and DFS in patients with cancers. However, in the subgroup analysis for OS, we only found the association in 13 types of cancers except for the ones in esophageal adenocarcinoma and ovarian carcinoma. In addition, through TCGA datasets, we observed the poor prognosis in 14 types of cancers. Consistent results were found in six types of cancers. Patients with high expressed HMGA2 in ccRCC, head and neck cancer, hepatocellular carcinoma and pancreatic ductal adenocarcinoma showed a significant shorter OS than patients with a low level of HMGA2 expression. However, in esophageal adenocarcinoma and ovarian carcinoma, we did not observe any significant correlation.

We then explored the relationship between clinicopathological features and high HMGA2 expression in our enrolled studies. We found the level of HMGA2 was positively associated with TNM stage, tumor differentiation, tumor invasion depth, lymph node metastasis, lymphovascular invasion, and vascular invasion, which indicated that HMGA2 might have a significant relationship with advanced features of cancer. Previous research performed by [@B5] found that HMGA2 protein levels were increased in all metastatic lung cancer cell lines compared with benign tumors and normal cells. According to [@B35], HMGA2 might play a significant role in the late stages of pancreatic carcinogenesis and in the progression towards a more aggressive tumor phenotype. In addition, HMGA2 was demonstrated to play a critical role in epithelial-to-mesenchymal transition (EMT) in various cancers such as gastric cancer ([@B58]), hepatocellular carcinoma ([@B24]) and nasopharyngeal cancer ([@B53]), thus inducing epithelial cancer invasion and metastasis.

Since the high expression of HMGA2 could be potentially an indicator of poor prognosis in patients with certain cancers, HMGA2 was expected to be a new therapeutic biomarker in cancers. Recently, Zhao et al. demonstrated that by directly targeting HMGA2, miR-599 could serve tumor suppressive roles in ccRCC ([@B60]). A study conducted by [@B26] suggested silencing HMGA2 expression in ovarian cancer cells could have a therapeutic effect on ovarian cancer. [@B22] reported the raf kinase inhibitor protein can inhibit the survival and invasion of gastric cancer cells and promote apoptosis through regulating the expression of HMGA2 and Osteopontin. The findings of [@B3] suggested that HMGA2 could become a therapeutic target by blocking HMGA2 protein expression in retinoblastoma cells or through inhibiting expression of the HMGA2 gene by targeting its promoters. [@B47] found radiotherapy significantly reduced the relative risk death in HMGA2-positive colorectal cancers (CRCs), but not in HMGA2-negative CRCs. All these studies showed HMGA2 could play a key role in cancers, which supported it potential role as a biomarker for cancer therapy.

However, some limitations of this study should be acknowledged. Firstly, heterogeneity in our study was substantial, which might be attributed to differences in types of cancers, study areas and cut-off values. Secondly, in the process of data extraction, we evaluated the HRs and 95% CIs from the Kaplan--Meier survival curves in five studies rather than directly obtained from the studies, which might be less accurate than extracting directly from published statistics. Thirdly, since negative results would have little chance to be published, there may be a bias in the published studies. Therefore, although no significant publication bias was detected in this meta-analysis, the results of our meta-analysis still need to be verified by a larger number of studies.

Despite the limitations described, our meta-analysis revealed the significance of HMGA2. Our meta-analysis showed that HMGA2 likely played an important role in human cancers and overexpression of HMGA2 could be associated with aggressive biological behavior although its prognostic values varied in different types of cancers. Specifically, overexpression of HMGA2 was significantly associated with poor prognosis in patients with ccRCC, head and neck cancer, hepatocellular carcinoma and pancreatic ductal adenocarcinoma, but not esophageal adenocarcinoma and ovarian carcinoma.
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